Celltrion has revolutionized the biotech industry by developing the world’s first antibody biosimilar. Despite initial skepticism regarding the feasibility of creating biosimilars for complex monoclonal antibodies, Celltrion’s breakthrough has ushered in a new era for antibody biosimilars.
At the European Academy of Dermatology and Venereology (EADV) conference in Paris on September 18, Professor Fernando de Mora from the School of Pharmacy of the Autonomous University of Barcelona hailed this achievement as a game-changer. He remarked that there was a time when many believed that biosimilars for monoclonal antibodies were impossible, and Celltrion proved them wrong.
Celltrion Meets Stringent Regulatory Standards, Expands into Dermatology
Professor de Mora emphasized Celltrion’s success in adhering to rigorous regulatory requirements, producing biosimilars that are virtually indistinguishable from their reference products. This breakthrough has allowed infliximab patients to switch to more affordable options, thereby freeing up healthcare resources. He added that since Celltrion’s initial success, it has seen over 70 antibody biosimilars gain approval.
The professor also highlighted the significance of expanding into dermatology. He stated that two decades ago, he might have hesitated to answer this question, but now, there’s no doubt. Further noting that the proven efficacy across various medical specialties will translate into earlier interventions for a broader range of dermatology patients.
Beyond Cost Savings: Innovation, Supply Stability, and Early Treatment
Professor de Mora argued that biosimilars offer benefits far beyond mere cost reduction. He explained that the competition has driven prices down, improving access. Further adding that more importantly, biosimilars are catalyzing innovation. He cited the development of subcutaneous infliximab as a prime example, noting how it has enhanced convenience for both patients and healthcare providers.
Discussing the shift in treatment paradigms, de Mora observed, increased accessibility has challenged the old norm of treating only severe cases. Now, they are witnessing earlier interventions in moderate stages of diseases. On the topic of supply stability, he added that having multiple equivalent options ensures treatment continuity even if issues arise with one product, providing peace of mind for patients.
Looking to the future, Professor de Mora expressed optimism about Celltrion’s potential. He suggested that they are well-positioned to tackle more complex challenges, such as next-generation biosimilars. He further added that personally, he sees opportunities for further innovation, perhaps exploring new indications beyond those of the original products.